Impact of VEGF gene polymorphisms in elderly cancer patients: Clinical outcome and toxicity

David Della-Morte, Silvia Riondino, Patrizia Ferroni, Raffaele Palmirotta, Donatella Pastore, Davide Lauro, Fiorella Guadagni, Mario Roselli

Research output: Contribution to journalArticlepeer-review


Vascular endothelial growth factors (VEGFs) are the key regulators in angiogenesis and have been shown to play a significant role in the progression and prognosis of angiogenesis-related diseases, such as cancer. VEGF inhibitors are a current pharmacological tumoral strategy. However, despite the strong association between aging and cancer incidence and progression, recent findings suggest impaired angiogenesis accompanied by a reduced expression of VEGF in cells derived from aging subjects. Specific variations of VEGF genes have been demonstrated to be genetic determinants for susceptibility, outcome and therapy response, especially for the solid tumors. Considering the complications present in frail elderly patients, analysis of VEGF genetic polymorphisms in these subjects may further help in tailoring an angiogenic pharmacological strategy, and in improving our ability to better understand prognosis during therapy-related to cancer.

Original languageEnglish
Pages (from-to)61-78
Number of pages18
Issue number1
Publication statusPublished - Jan 1 2015


  • angiogenesis
  • cancer
  • elderly
  • genetics
  • single nucleotide polymorphisms
  • tumor prognosis
  • vascular endothelial growth factors
  • VEGF
  • VEGF inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine
  • Medicine(all)


Dive into the research topics of 'Impact of VEGF gene polymorphisms in elderly cancer patients: Clinical outcome and toxicity'. Together they form a unique fingerprint.

Cite this